Literature DB >> 2941407

Comparative study of MDL 17043 and MDL 19205, new positive inotropic agents, by use of isolated, blood-perfused dog-heart preparations.

Y Wada, N Taira.   

Abstract

The cardiac and coronary vasodilator effects of MDL 17043 and MDL 19205 were compared in isolated, blood-perfused papillary muscle, sinoatrial (SA) node, and atrioventricular (AV) node preparations of dogs. In these preparations, MDL 17043 (0.01-3 mumol) and MDL 19205 (0.01-3 mumol) were injected intra-arterially. Both drugs increased the force of contraction of papillary muscles paced at a rate of 120 stimuli/min, and a ten-fold increase in dose produced about a 100% increase in the force. The two drugs increased the sinus rate in SA node preparations, and a tenfold increase in dose resulted in about a 12% increase in sinus rate with MDL 17043 and about a 17% increase with MDL 19205. These drugs increased the rate of automaticity of spontaneously beating papillary muscles and also the force of contraction. With a ten-fold increase in dose, the increase in the rate was about 16% for MDL 17043 and about 9% for MDL 19205. No ventricular arrhythmias were produced by either drug. The drugs equally decreased AV conduction time by accelerating AV nodal conduction in AV node preparations whose right atria were paced at a rate of 150 stimuli/min. However, the decrease remained about 5% with a ten-fold increase in dose of both drugs. No AV junctional tachycardia was produced. In all preparations, both drugs increased (coronary) blood flow. In paced papillary muscle preparations a tenfold increase in dose resulted in about a 37% increase in blood flow with MDL 17043 and about a 42% increase with MDL 19205.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941407     DOI: 10.1007/bf02060241

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  12 in total

1.  Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.

Authors:  M Endoh; T Yanagisawa; T Morita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1985-07       Impact factor: 4.030

2.  Pharmacological evidence of autonomic nerve activities in canine papillary muscle.

Authors:  M Endoh; K Hashimoto
Journal:  Am J Physiol       Date:  1970-05

3.  Effect of manganese ions on the contraction and automaticity of the blood-perfused canine papillary muscle.

Authors:  M Endo; T Kimura; K Hashimoto
Journal:  Jpn J Pharmacol       Date:  1974-10

4.  Selective stimulation of the parasympathetic preganglionic nerve fibres in the excised and blood-perfused SA node preparation of the dog.

Authors:  K Kubota; K Hashimoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  The isolated and cross-circulated AV node preparation of the dog.

Authors:  K Hashimoto; T Iijima; N Taira
Journal:  Tohoku J Exp Med       Date:  1972-07       Impact factor: 1.848

6.  Effect of MDL 17043, a new cardiotonic agent, on myocardial oxygen consumption.

Authors:  L E Roebel; R J Hodgeman; N L Velayo; R C Dage; J K Woodward
Journal:  J Pharm Pharmacol       Date:  1983-04       Impact factor: 3.765

7.  Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043.

Authors:  T Kariya; L J Wille; R C Dage
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

8.  Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one).

Authors:  R C Dage; L E Roebel; C P Hsieh; D L Weiner; J K Woodward
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

9.  Cardiovascular properties of a new cardiotonic agent, MDL 19205.

Authors:  R C Dage; L E Roebel; C P Hsieh; J K Woodward
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jan-Feb       Impact factor: 3.105

10.  Characterization of the cardiovascular activities of a new cardiotonic agent, MDL 17043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazole-2-one).

Authors:  L E Roebel; R C Dage; H C Cheng; J K Woodward
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

View more
  4 in total

1.  T-1583 and forskolin are similar in their cardiac effects and dissimilar in their vascular effects.

Authors:  M Hosono; K Satoh; N Taira
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

2.  Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.

Authors:  T Hosokawa; T Mori; H Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; M Tominaga; Y Yabuuchi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

3.  Cardiac and coronary vasodilator profile of pimobendan, a new cardiotonic drug, revealed by use of isolated, blood-perfused dog heart preparations.

Authors:  J Imagawa; K Satoh; N Taira
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

4.  Comparative study of cardiovascular profiles of milrinone and amrinone by use of isolated, blood-perfused dog heart preparations.

Authors:  Y Sato; Y Wada; N Taira
Journal:  Heart Vessels       Date:  1986       Impact factor: 2.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.